How many mg of Mounjaro you should take — and why the answer isn't yours to decide alone

What the clinical evidence says about starting dose and the escalation schedule

The tirzepatide dosing schedule was not designed arbitrarily. It emerged from a large-scale clinical programme, most prominently the SURMOUNT-1 trial, which enrolled 2,539 adults with obesity over 72 weeks and tested tirzepatide at 5 mg, 10 mg and 15 mg maintenance doses, each preceded by a structured escalation period. Average body-weight reductions reached around 20–21% at the 15 mg dose. Critically, the trial used exactly the same gradual titration approach that now appears in the licensed prescribing guidance: participants did not start at a high dose and work backwards. They started low, moved up at set intervals, and the tolerability data showed why that matters.

The Summary of Product Characteristics, available in full on the electronic Medicines Compendium (eMC), is the document your prescriber works from. It sets the schedule clearly: 2.5 mg for the first four weeks, then 5 mg, then dose increases of 2.5 mg every four weeks thereafter up to the maximum 15 mg. What the SmPC does not do is tell any individual which dose they will stay on, and if you are working through what dose of Mounjaro you should take, that depends on how your body responds and on an ongoing clinical conversation, not a predetermined plan.

For a broader look at how the treatment works and what the full Mounjaro overview covers, that page is a practical starting point before thinking about specific milligrams.

Why the 2.5 mg starting pen exists, and what "titration" really means in practice

The first pen's job is adjustment. Gastrointestinal side effects (nausea, loose stools, reduced appetite) are most pronounced at the start of treatment and after dose increases. By holding at 2.5 mg for a full four weeks, the prescribing schedule gives your digestive system time to adapt before the dose goes up. Skipping or shortening that adjustment period is associated with worse tolerability, not faster results.

Titration is the clinical term for this step-by-step process, and it applies across the full schedule. Moving from 2.5 mg to 5 mg, from 5 mg to 7.5 mg, and so on, each step is conditional on the previous one being tolerated. If side effects at a given dose are significant, the right clinical response is often to stay at that dose for longer rather than pressing upward. If you are wondering whether it is time to increase your dose, the answer depends on factors your prescriber can assess, your current side-effect profile, your weight trajectory, and how long you have been at the current level.

Some people reach a point where progress plateaus and ask whether a higher dose would help. Others find a mid-range dose well tolerated and effective and stay there. The evidence supports both outcomes: not everyone needs 15 mg, and the aim is always the highest dose that is clinically appropriate and tolerated, not simply the highest dose available.

The question of the "golden dose" and what the data actually shows at each level

A phrase that circulates in weight-management conversations is the idea of a "golden dose", a sweet spot where results are strong and side effects minimal. The clinical picture is more nuanced than that framing suggests. In the SURMOUNT-1 data, weight loss increased meaningfully with each higher maintenance dose: 5 mg, 10 mg and 15 mg each produced greater average reductions than the one below it. There is no fixed dose at which results peak and then plateau for everyone; the response curve varies between individuals.

For context on how individual doses compare in terms of what patients experience, the 5 mg Mounjaro page covers that strength in detail, and the question of when moving to 5 mg makes sense is explored separately. The NHS medicines page for tirzepatide also provides patient-level information on the dose schedule, side effects and storage that every person on treatment should be familiar with.

One practical note: dose reviews do not always land at a convenient moment. If you are approaching a bank holiday, a long holiday, or even a stretch where a Monday order before 12pm feels uncertain, it is worth flagging this to your prescribing team in advance. A clinical review cannot wait indefinitely, but a short conversation about timing can prevent a gap in supply.

How a prescriber reaches a dosing decision, and why this is not a decision to make by comparing notes online

The number of milligrams of tirzepatide that is right for you reflects a clinical judgement, not a formula. Prescribers weigh up how well the current dose is tolerated, how weight is tracking over time, whether any relevant health conditions have changed, and what you are actually experiencing week to week. Online accounts of what worked for someone else (even someone with a similar BMI and starting weight) are not a substitute for that assessment.

NICE's appraisal of tirzepatide, TA1026, is the framework UK prescribers and commissioners use when considering this treatment. It includes the condition that if less than 5% of body weight has been lost after six months at the highest tolerated dose, continuing treatment should be reviewed. That is a clinical decision point, not a reason to rush upward through the schedule prematurely.

At nume, every prescription is reviewed by a named GPhC-registered Independent Prescriber. The same clinician who approves your initial prescription reviews any request for a dose change, checking your progress and side-effect record before approving the next pen. There are no automated sign-offs. If you have questions about where you are in the schedule, speaking to our prescribers is the right first step, not extrapolating from trial averages or online forums.